April 1, 2003Current Pharmaceutical Design
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Key result
ACEi and ARBs reduce complications in myocarditis animal models by downregulating autoimmune components.
Why the study?
The effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on myocarditis have been less studied in animal models of frank myocarditis compared to other heart failure and hypertension models.
Do angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists improve outcomes in animal models of myocarditis?
Population
Animal models of myocarditis
Comparison
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists
Design
Review of published animal and in vitro studies
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change myocarditis management; leaves open translation of animal benefits to human trials.
Structured PICO
Do angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists improve outcomes in animal models of myocarditis?
P
Population
Animal models of myocarditis
I
Intervention
Angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, lisinopril) and angiotensin II receptor antagonists (e.g., losartan)
ACE inhibitors and ARBs appear beneficial in experimental models of myocarditis by reducing complications and modulating autoimmune responses without exacerbating the initiating infection.
Cite This Study
Godsel et al. (2003) conducted a review in Myocarditis. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists was evaluated. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists appear beneficial in animal models of myocarditis for reducing complications and downregulating autoimmune components.